Neurocrine Biosciences (NASDAQ:NBIX) Receives “Outperform” Rating from William Blair

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “outperform” rating reissued by research analysts at William Blair in a research report issued on Friday,RTT News reports.

Several other equities research analysts have also commented on NBIX. Wedbush restated an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group raised their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, Barclays upped their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $167.19.

Neurocrine Biosciences Stock Down 14.7 %

NASDAQ:NBIX traded down $22.18 on Friday, hitting $128.33. The stock had a trading volume of 1,159,535 shares, compared to its average volume of 977,102. The business’s fifty day moving average is $138.41 and its 200 day moving average is $131.64. The company has a market cap of $12.99 billion, a PE ratio of 34.43 and a beta of 0.33. Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. Equities analysts predict that Neurocrine Biosciences will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matt Abernethy sold 1,283 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $196,132.21. Following the transaction, the chief financial officer now directly owns 32,681 shares in the company, valued at $4,995,944.47. This trade represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 222,693 shares of company stock worth $32,718,279. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Edgestream Partners L.P. boosted its position in Neurocrine Biosciences by 138.8% during the 4th quarter. Edgestream Partners L.P. now owns 12,574 shares of the company’s stock worth $1,716,000 after acquiring an additional 7,308 shares during the last quarter. Lindbrook Capital LLC increased its position in Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after buying an additional 130 shares during the period. Raymond James Financial Inc. bought a new position in Neurocrine Biosciences during the 4th quarter worth $115,193,000. Arizona State Retirement System increased its position in shares of Neurocrine Biosciences by 1.6% in the fourth quarter. Arizona State Retirement System now owns 29,302 shares of the company’s stock worth $4,000,000 after purchasing an additional 469 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in Neurocrine Biosciences in the fourth quarter valued at about $4,714,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.